Acumen Pharmaceuticals Inc (ABOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,307 | -42,856 | -29,990 | -19,280 | -9,129 |
| Depreciation Amortization | -282 | 656 | 695 | 460 | 253 |
| Accounts payable and accrued liabilities | -878 | 552 | 996 | 580 | 121 |
| Other Working Capital | 24 | 3,986 | 3,172 | 2,720 | -41 |
| Other Operating Activity | 2,268 | 2,509 | 1,177 | 753 | 497 |
| Operating Cash Flow | $-10,175 | $-35,153 | $-23,950 | $-14,767 | $-8,299 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -41,927 | 39,346 | 59,731 | 3,731 | -5,090 |
| PPE Investments | N/A | -161 | -126 | -45 | -9 |
| Investing Cash Flow | $-41,927 | $39,185 | $59,605 | $3,686 | $-5,099 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 3,907 | 19 | 17 | N/A |
| Other Financing Activity | 0 | 0 | -296 | -31 | 0 |
| Financing Cash Flow | $0 | $3,907 | $-277 | $-14 | $N/A |
| Beginning Cash Position | 130,101 | 122,162 | 122,162 | 122,162 | 122,162 |
| End Cash Position | 77,999 | 130,101 | 157,540 | 111,067 | 108,764 |
| Net Cash Flow | $-52,102 | $7,939 | $35,378 | $-11,095 | $-13,398 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,175 | -35,153 | -23,950 | -14,767 | -8,299 |
| Capital Expenditure | N/A | -161 | -126 | -45 | -9 |
| Free Cash Flow | -10,175 | -35,314 | -24,076 | -14,812 | -8,308 |